Thyrocare Technologies Ltd

As of March 31, 2026, Thyrocare Technologies Ltd carries a market capitalization of 55.67B, placing it among publicly traded companies globally. Its enterprise value stands at 53.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Thyrocare Technologies Ltd's next confirmed earnings release is scheduled for November 4, 2026.

As of March 31, 2026, Thyrocare Technologies Ltd has 159.16M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Thyrocare Technologies Ltd maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Thyrocare Technologies Ltd recorded 352.60M in income tax expense.

As of the close on October 22, 2026, Thyrocare Technologies Ltd's stock has gained approximately 12.83% over the past 52 weeks. The 50-day moving average sits at 557.32, while the 200-day moving average is 485.58.

As of March 31, 2026, Thyrocare Technologies Ltd holds 2.31B in cash and equivalents against 506.90M in total debt, resulting in a net debt position of -383.20M. Total book value stands at 5.86B, with working capital of 2.62B providing operational flexibility.

Thyrocare Technologies Ltd's most recent stock split took place on November 28, 2025 with a 1:3 split ratio.